Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Omega Funds Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
7,420,086Website Global Rank
530Website Monthly Traffic
Twitter Followers
Description
Strategically advanced, they enable you to benefit from the expertise of institutional portfolio managers all for a minimum investment of $500! Omega FundsTM give you the opportunity to diversify your investment portfolio and maximize return potential.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2016 | Morphic Therapeutic | Series A | 0 |
| 1/2007 | Achaogen | Venture Round | - |
| 5/2017 | Anaconda BioMed | Series A | 16.9M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 1/2004 | Evotec | Venture Round | - |
| 1/2004 | Ardana Bioscience | Venture Round | - |
| 1/2004 | CropDesign | Venture Round | - |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 1/2002 | Epigenomics | Venture Round | - |
| 5/2013 | SpineVision | Venture Round | 10M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 12/2013 | Visterra | Series A | 8.1M |
| 1/2005 | DBV Technologies | Venture Round | - |
| 12/2017 | Translate Bio | Series C | 42M |
| 9/2021 | Vanqua Bio | Series B | 85M |
| 7/2017 | Trevi Therapeutics | Series C | 30M |
| 1/2019 | Trevi Therapeutics | Series C | 10M |
| 9/2010 | Hydrocision | Venture Round | - |
| 7/2014 | Paratek Pharmaceuticals | Post-IPO Debt | 93M |
| 9/2021 | Anjarium Biosciences | Series A | 60.4M |
| 2/2018 | Senti Biosciences | Series A | 53M |
| 4/2014 | JenaValve Technology | Series C | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 12/2007 | Santaris Pharma | Series C | 30M |
| 7/2013 | JenaValve Technology | Series C | 62.5M |
| 1/2023 | SoniVie | Series C | 0 |
| 6/2014 | BioSilta | Venture Round | 3.4M |
| 4/2015 | Jounce Therapeutics | Series B | 0 |
| 12/2019 | Anaconda BioMed | Series B | 22.2M |
| 9/2018 | First Wave Bio | Venture Round | 2.6M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 1/2004 | Acrux | Venture Round | - |
| 1/2011 | Exenta | Venture Round | - |
| 4/2017 | Sienna Biopharmaceuticals | Series B | 0 |
| 9/2021 | Thankful | Series A | 12M |
| 9/2017 | Immunic Therapeutics | Series A | 11.9M |
| 8/2022 | eTheRNA immunotherapies | Series B | 0 |
| 9/2017 | Replimune Group | Series B | 55M |
| 1/2018 | Gossamer Bio | Series A | 100M |
| 7/2020 | Alpine Immune Sciences | Post-IPO Equity | 60M |
| 5/2012 | Egalet | Series B | 14.3M |
| 10/2017 | Visterra | Series C | 0 |
| 1/2018 | ESSA Pharma | Post-IPO Equity | 5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 1/2021 | Ikena Oncology | Series B | 0 |
| 11/2022 | NRG Therapeutics | Series A | 18.2M |
| 1/2004 | CymaBay Therapeutics | Venture Round | - |
| 12/2020 | Syros Pharmaceuticals | Post-IPO Equity | 90.5M |
| 1/2012 | Translate Bio | Series A | 20.7M |
| 8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
| 8/2018 | Trevi Therapeutics | Series C | 10.5M |
| 5/2018 | Attenua | Series A | 35M |
| 1/2010 | ImpactRx | Series E | 0 |
| 6/2018 | Andrew Alliance | Series C | 0 |
| 8/2015 | Telesta Therapeutics | Venture Round | 0 |
| 6/2015 | XTuit Pharmaceuticals | Series A | 22M |
| 7/2015 | Translate Bio | Series B | 0 |
| 11/2015 | ObsEva | Series B | 60M |
| 6/2018 | Kronos Bio | Seed Round | 0 |
| 1/2021 | Endeavor BioMedicines | Series A | 62M |
| 11/2006 | Neurotech | Series B | 0 |
| 3/2015 | GelSight | Series A | - |
| 12/2019 | IFM Therapeutics | Venture Round | 55.5M |
| 6/2015 | Kezar Life Sciences | Series A | 23M |
| 11/2021 | Chroma Medicine | Series A | 125M |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 7/2019 | Kronos Bio | Series A | 105M |
| 6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
| 9/2015 | Replimune Group | Series A | 30M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 4/2022 | CDR-Life AG | Series A | 0 |
| 5/2020 | Atea | Series D | 215M |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 7/2015 | Median Technologies | Post-IPO Equity | 22M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 11/2012 | Visterra | Series A | 26.1M |
| 1/2017 | Translate Bio | Series C | 51M |
| 7/2013 | Dicerna Pharmaceuticals | Series C | 0 |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 9/2022 | Photys | Series A | 0 |
| 9/2018 | Morphic Therapeutic | Series B | 0 |
| 10/2020 | Scorpion Therapeutics | Series A | 108M |
| 10/2019 | Nuvation Bio | Series A | 275M |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 3/2020 | Amunix | Series A | 0 |
| 10/2014 | Visterra | Series B | 30M |
| 5/2009 | Elixir Pharmaceuticals | Series D | 12M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 10/1999 | Eve.com | Venture Round | - |
| 3/2007 | Intarcia Therapeutics | Venture Round | 50M |
| 4/2021 | Icosavax | Series B | 0 |
| 8/2015 | Editas Medicine | Series B | 0 |
| 2/2014 | Egalet | Post-IPO Equity | - |
| 6/2023 | Upstream Bio | Series B | 0 |
| 11/2009 | Oxagen | Series C | 0 |
| 8/2014 | Median Technologies | Post-IPO Equity | 26.4M |
| 11/2020 | Adagio Therapeutics | Series B | 0 |
| 6/2021 | Synthekine | Series B | 0 |
| 3/2023 | Bicara Therapeutics | Series B | 0 |
| 3/2022 | Aerium Therapeutics | Series A | - |
| 6/2023 | ARTBIO | Seed Round | 0 |
| 6/2023 | Artbio | Seed Round | 0 |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 1/2021 | Scorpion Therapeutics | Series B | 162M |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 4/2021 | Adagio Therapeutics | Series C | 0 |
| 6/2020 | Sana Biotechnology | Series A | 700M |
| 3/2005 | Celletra | Venture Round | 5.7M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 1/2004 | Develogen AG | Venture Round | - |
| 1/2014 | NeuroVision Imaging | Venture Round | - |
| 1/2004 | Eurobio-Scientific | Venture Round | - |
| 8/2014 | Andrew Alliance | Series B | - |
| 1/2011 | OnPath Technologies | Venture Round | - |
| 1/2001 | Enanta Pharmaceuticals | Venture Round | - |
| 5/2015 | Replimune Group | Seed Round | 2M |
| 6/2022 | Upstream Bio | Series A | 200M |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 10/2020 | Chord Therapeutics | Series A | 16M |
| 6/2020 | eTheRNA immunotherapies | Series B | 0 |
| 3/2021 | Amunix | Series B | 117M |
| 6/2022 | Upstream Bio | Series A | 0 |
| 4/2022 | CDR-Life AG | Series A | 0 |
| 3/2022 | Aerium Therapeutics | Series A | - |
| 2/2022 | Endeavor BioMedicines | Series B | 0 |
| 11/2021 | Chroma Medicine | Series A | 0 |
| 10/2021 | Rectify Pharmaceuticals | Series A | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 9/2021 | Thankful | Series A | 0 |
| 9/2021 | Anjarium Biosciences | Series A | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
